The U.S. Food and Drug Administration (FDA) has issued draft guidance aimed at reducing unnecessary animal testing in the safety assessments of certain cancer drugs. This measure intends to accelerate drug development while decreasing the use of non-human primates and other animals in testing.
What happened
The FDA’s draft guidance, titled “Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products,” outlines recommendations for conducting general toxicology studies with less reliance on animal models. Key proposals include eliminating animal testing when drugs show no pharmacologic or binding activity, using a single relevant species rather than two, and replacing some long-term primate studies with risk assessments based on existing data and New Approach Methodologies (NAMs).
These NAMs include alternative, evidence-based methods detailed in recent FDA resources, supporting weight-of-evidence approaches to non-animal testing. The guidance also encourages rodent-only studies in certain contexts and limits the use of three-month non-human primate studies where scientifically justified.
Why it matters
This guidance is part of the FDA’s broader initiative to shorten the lengthy drug development timeline, which can currently span 10 to 12 years on average. It reflects a commitment to more ethical research practices by reducing animal use and leveraging alternative methods validated during urgent drug development periods, such as the COVID-19 pandemic.
By recommending streamlined safety assessments, the FDA aims to facilitate faster patient access to important oncology therapies, while maintaining rigorous safety standards. It also aligns with international harmonization efforts, supplementing prior FDA and International Council for Harmonisation (ICH) guidance on oncology drug testing.
Background
Nonclinical safety testing traditionally involves multiple animal species to evaluate potential toxic effects before human trials. However, advances in pharmacology and alternative testing methods have prompted regulators to reconsider these requirements. The COVID-19 pandemic accelerated the adoption of reduced primate testing approaches due to urgency and ethical considerations.
The FDA invites public comments on the draft guidance until July 30, 2026, after which it will review input before finalizing the recommendations.
Sources
This article is based on reporting and publicly available information from the following source:
Read more Health & Public Health stories on Goka World News.